News NKGen Biotech, Inc.

Equities

NKGN

US65488A1016

End-of-day quote Nasdaq Other stock markets 03:30:00 05/06/2024 am IST			5-day change	1st Jan Change
1.45 ^USD	+0.69%		-13.17%	-47.27%

03/06	NKGen Biotech, Inc. To Present Updated Phase 1 Data on SNK02 Allogeneic NK Cell Therapy in Solid Tumors at the 6th Annual Allogeneic Cell Therapies Summit 2024	CI
23/05	NKGen Biotech Publishes Phase 1 Interim Analysis Results of SNK02 Allogeneic NK Cell Therapy in Advanced Solid Tumors at the 2024 American Society of Clinical Oncology Annual Meeting	CI

Summary

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

NKGen Biotech To Present Updated Phase 1 Data on SNK02 Allogeneic NK Cell Therapy in Solid Tumors at the 6th Annual Allogeneic Cell Therapies Summit 2024	03/06	AQ
NKGen Biotech, Inc. To Present Updated Phase 1 Data on SNK02 Allogeneic NK Cell Therapy in Solid Tumors at the 6th Annual Allogeneic Cell Therapies Summit 2024	03/06	CI
Spotlighting Unexplored Stocks in Focus: NKGN, INBS, BTBT, PRSO, MGOL	24/05	AQ
NKGen Biotech Publishes Phase 1 Interim Analysis Results of SNK02 Allogeneic NK Cell Therapy in Advanced Solid Tumors at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting	24/05	AQ
NKGen Biotech Publishes Phase 1 Interim Analysis Results of SNK02 Allogeneic NK Cell Therapy in Advanced Solid Tumors at the 2024 American Society of Clinical Oncology Annual Meeting	24/05	CI
NKGen Biotech, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	21/05	CI
Sector Update: Health Care Stocks Softer Late Afternoon	21/05	MT
Top Midday Gainers	20/05	MT
Sector Update: Health Care Stocks Ease Monday Afternoon	20/05	MT
NKGen Biotech Cell Therapy Gets Clearance to Start Phase 2 Clinical Trial in Alzheimer's Disease; Shares Rise	20/05	MT
NKGen Biotech’s SNK01 NK Cell Therapy Cleared to Start Phase 2 Clinical Trial in Alzheimer’s Disease	20/05	AQ
NKGen Biotech, Inc.?s SNK01 NK Cell Therapy Cleares to Start Phase 2 Clinical Trial in Alzheimer?s Disease	20/05	CI
NKGen Biotech Announces Upcoming Presentation on Autologous NK Cell Therapy at the 5th International Cell & Gene Therapy China Summit & Exhibition	16/05	AQ
NKGen Biotech, Inc. announced that it has received $0.2 million in funding from Meteora Capital, LLC, Glazer Capital, LLC	01/05	CI
NKGen Biotech Announces FDA Clearance of Investigational New Drug (IND) Application for SNK01 NK Cell Therapy in Parkinson’s Disease	29/04	AQ
Nkgen Biotech Announces FDA Clearance of Investigational New Drug Application for SNK01 NK Cell Therapy in Parkinson's Disease	29/04	CI
NKGen Biotech, Inc. announced that it has received $0.55 million in funding from FirstFire Capital Management LLC, Meteora Capital, LLC, Glazer Capital, LLC, Meteora Strategic Capital, LLC, Sandia Investment Managment LP	29/04	CI
NKGen Biotech Presents Updated NK Cell Therapy Data for Neurodegenerative Disease at the 12th Annual Alzheimer’s & Parkinson’s Drug Development Summit	26/04	AQ
NKGen Biotech Announces Upcoming Publication at the 2024 American Society of Clinical Oncology Annual Meeting	25/04	AQ
NKGen Biotech Announces Upcoming Publication at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting	25/04	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News NKGen Biotech, Inc.

Equities

NKGN

US65488A1016

Summary

Filters